Practice variation among Michigan neurologists in the use of intravenous heparin

Journal of the Neurological Sciences

Volumn 202, Issue 1-2, 2002, Pages 25-27

  Kudesia, Rashmi ^a   Chaturvedi, Seemant ^a  

^a WAYNE STATE UNIVERSITY   (United States)

Author keywords

Acute ischemic stroke; Anticoagulation; Atrial fibrillation; Heparin

Indexed keywords

HEPARIN;

ARTICLE; CONTROLLED STUDY; HEALTH SURVEY; HEART ATRIUM FIBRILLATION; HEART RHYTHM; HUMAN; MEDICAL PRACTICE; MEDICOLEGAL ASPECT; NEUROLOGY; PRIORITY JOURNAL; STROKE; TRANSIENT ISCHEMIC ATTACK;

ATRIAL FIBRILLATION; CEREBROVASCULAR ACCIDENT; DATA COLLECTION; HEPARIN; HUMANS; INJECTIONS, INTRAVENOUS; MICHIGAN; NEUROLOGY; PHYSICIAN'S PRACTICE PATTERNS;

EID: 0037110411     PISSN: 0022510X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-510X(02)00127-2     Document Type: Article

References (17)

1. Adams H.P., Brott T.G., Crowell R.M.et al. Guidelines for the management of patients with acute ischemic stroke: a statement for healthcare professionals from a special writing group of the Stroke Council, American Heart Association. Stroke. 25:1994;1901-1914.
2. The International Stroke Trial (IST): a randomized trial of aspirin, subcutaneous heparin, both, or neither among 19,435 patients with acute ischemic stroke. Lancet. 349:1997;1569-1581.
3. Low molecular weight heparinoid, ORG 10172 (danaparoid), and outcome after acute ischemic stroke. JAMA. 279:1998;1265-1272.
4. Berge E.et al. Low molecular-weight heparin versus aspirin in patients with acute ischemic stroke and atrial fibrillation: a double-blind randomized study. Lancet. 355:2000;1205-1210.
5. Diener H.C., Ringelstein E.B., von Kummer R.et al. Treatment of acute ischemic stroke with the low-molecular-weight heparin certoparin. Stroke. 32:2001;22-29.
6. Kay R., Wong K.S., Yu Y.L.et al. Low-molecular-weight heparin for the treatment of acute ischemic stroke. N. Engl. J. Med. 333:1995;1588-1593.
7. Bath P.M., Lindenstrom E., Boysen G.et al. Tinzaparin in acute ischemic stroke (TAIST): a randomised aspirin-controlled trial. Lancet. 358:2001;702-710.
8. Swanson R.A. Intravenous heparin for acute stroke: what can we learn from the megatrials? Neurology. 52:1999;1746-1750.
9. Anderson D.C. How twin cities neurologists treat ischemic stroke? Arch. Neurol. 50:1993;1098-1103.
10. American Academy of Neurology 2000-2001 Membership Directory.
11. Saxena R., Lewis S., Berge E.et al. Risk of early death and recurrent stroke and effect of heparin in 3169 patients with acute ischemic stroke and atrial fibrillation in the International Stroke Trial. Stroke. 32:2001;2333-2337.
12. Secondary prevention in non-rheumatic atrial fibrillation after transient ischemic attack or minor stroke. Lancet. 342:1993;1255-1262.
13. Castillo J., Davalos A., Noya M. Progression of ischaemic stroke and excitotoxic aminoacids. Lancet. 349:1997;79-83.
14. Caplan L.R. Brain embolism, revisited. Neurology. 43:1993;1281-1287.
15. A randomized, blinded, trial of clopidogrel versus aspirin in patients at risk of ischemic events (CAPRIE). Lancet. 348:1996;1329-1339.
16. Diener H.C., Cunha L., Forbes C.et al. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke: European stroke prevention study 2. J. Neurol. Sci. 143:1996;1-13.
17. Villar-Cordova C., Morgenstern L.B., Barnholtz J.S., Frankowski R.F., Grotta J.C. Neurologists' attitudes regarding rt-PA for acute ischemic stroke. Neurology. 50:1998;1491-1494.